Has Anyone Gotten Thyroid Cancer From Ozempic? What the Cases and the Studies Actually Show

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Topic: thyroid cancer signal in GLP-1 pharmacovigilance

Key Takeaways

• Yes, individual patients have been diagnosed with thyroid cancer while taking Ozempic; these are documented in FAERS and case reports
• Causation is a separate question from co-occurrence; individual cases cannot prove the medication caused the cancer
• The largest available U.S. population study (Wang et al., JAMA 2024) did not find a statistically significant overall increase in thyroid cancer among GLP-1 users compared to matched controls
• The boxed warning is about medullary thyroid carcinoma (MTC) specifically; other thyroid cancer types have not shown a clear GLP-1 association
• Routine ultrasound screening of asymptomatic GLP-1 patients is not recommended; symptom-based surveillance is the standard approach

Direct answer

Yes, people have been diagnosed with thyroid cancer while taking Ozempic. Whether the medication caused the cancer is a different question. Individual cases are documented in the FDA Adverse Event Reporting System and in published medical case reports. They look alarming in isolation. Population-scale studies tell a different story: the 2024 Wang JAMA paper covering tens of thousands of GLP-1 users found no statistically significant overall increase in thyroid cancer compared to similar patients on other diabetes medications. The evidence to date does not support a clear causal link, while leaving the long-term question open enough that surveillance continues.

Table of contents

1. The question patients are actually asking
2. FAERS reports and what they can and cannot tell us
3. The 2024 Wang JAMA study in detail
4. Published case reports of thyroid cancer in GLP-1 users
5. Why MTC is the cancer type the warning is built around
6. The active litigation landscape, briefly
7. What clinical societies recommend for surveillance
8. Decision framework for patients on Ozempic with thyroid concerns
9. The contrary view: when individual reports outweigh population data
10. FAQ
11. Sources

The question patients are actually asking

"Has anyone gotten thyroid cancer from Ozempic" is a real question with a layered answer. People asking it usually want two things at once. They want to know if anyone has been diagnosed (a yes-or-no factual question) and they want to know if the medication caused it (a much harder scientific question).

The factual answer is yes; thyroid cancer diagnoses have occurred in patients taking Ozempic and have been reported through multiple channels. The causal answer is uncertain, with population data leaning toward no detectable increase and rodent data and the boxed warning maintaining caution.

The two answers need to be held together. Saying only the first leaves people frightened in a way the science does not support. Saying only the second sounds dismissive of patients who feel something happened to them.

FAERS reports and what they can and cannot tell us

The FDA Adverse Event Reporting System is a passive surveillance database. Clinicians, patients, manufacturers, and others can submit reports of adverse events that occurred in patients taking a medication. The system has been operating in its current form for decades and contains millions of reports across all approved drugs.

FAERS is good at flagging signals. When a particular adverse event starts appearing in numbers larger than expected for a given medication, it can trigger more formal study.

FAERS is poor at measuring incidence or proving causation. The reporting is voluntary, which produces selection bias. Patients with concerning outcomes are more likely to be reported than patients without. Media coverage, lawsuits, and patient communities all influence reporting rates. The denominator is not knowable in any reliable way.

For Ozempic and thyroid cancer specifically, FAERS contains a sizable number of reports accumulated since approval. The volume reflects real events but also reflects the high prescribing volume of the drug and the public awareness of the boxed warning. A patient diagnosed with thyroid cancer while on Ozempic is more likely to be reported than a patient diagnosed with the same cancer who is not on the drug, because the association is on everyone's mind. That asymmetry is exactly the kind of bias FAERS cannot adjust for.

The 2024 Wang JAMA study in detail

The 2024 Wang and colleagues paper in JAMA used a large U.S. claims database to compare thyroid cancer incidence between GLP-1 receptor agonist users and patients on other glucose-lowering therapies. The study design addressed many of the limitations of FAERS and earlier observational work.

Key features of the analysis:

• Active comparator design (GLP-1 users vs patients on other diabetes medications, not vs untreated patients)
• New-user design (patients followed from start of medication, not prevalent users)
• Adjustment for cancer risk factors including age, sex, smoking, family history when available, and prior healthcare utilization
• Multiple analytic approaches to address confounding by indication and healthy-user bias

The headline finding was no statistically significant overall increase in thyroid cancer among GLP-1 users. Hazard ratios crossed 1.0 in primary and most secondary analyses. Subgroup analyses by age, sex, and duration of therapy were largely consistent. The authors noted that follow-up was limited (typically 3-5 years), so very long-latency effects could be missed.

The paper joined a growing body of large epidemiologic work that has not confirmed the rodent-based concern in human populations. Earlier studies including Bezin et al. 2023 in Diabetes Care had also explored the question with mixed results; the Wang paper added a large and methodologically rigorous data point on the reassuring side.

Published case reports of thyroid cancer in GLP-1 users

Individual case reports of thyroid cancer in patients on GLP-1 medications appear in the medical literature. Some describe medullary thyroid carcinoma specifically; others describe papillary or follicular cancers, which are biologically distinct.

Case reports are valuable in medicine because they raise questions and describe unusual presentations. They are not, individually, evidence of causation. Thyroid cancer occurs at a meaningful baseline rate in the U.S. population (roughly 14 cases per 100,000 per year, mostly papillary). Among the millions of patients prescribed GLP-1 medications, some would be expected to develop thyroid cancer by chance alone.

The case reports are useful for understanding presentation patterns and for prompting larger studies. They are not useful for estimating how often the medication causes a cancer it did not cause in any individual patient.

Why MTC is the cancer type the warning is built around

The boxed warning specifically names medullary thyroid carcinoma (MTC) because that is the cancer type observed in rodent toxicology studies. MTC arises from thyroid parafollicular cells, the C-cells, which produce calcitonin. C-cells express GLP-1 receptors in some species.

MTC is rare in humans, accounting for roughly 1-2% of all thyroid cancers. Most MTC cases are sporadic; about 25% are familial and associated with RET gene mutations (the MEN-2 syndromes). Patients with MEN-2 are at very high lifetime risk of MTC and are explicitly contraindicated for Ozempic.

The other thyroid cancer types (papillary 80%, follicular 10%, anaplastic 1-2%) arise from follicular cells, not C-cells. The biological connection to GLP-1 receptors is much weaker. The boxed warning does not specifically apply to these cancers, though pharmacovigilance covers all thyroid cancer types in aggregate.

For patients without MTC or MEN-2 history, the boxed warning is a precaution based on a rodent finding that has not been confirmed at population scale in humans.

The active litigation landscape, briefly

As of 2026 there is active litigation in the United States involving GLP-1 medications and various claimed adverse outcomes including thyroid cancer, pancreatic cancer, and other harms. Lawsuits are filed in multiple jurisdictions and have been consolidated in multidistrict litigation in some cases.

Lawsuits are not the same as scientific evidence. They reflect legal claims and the structural incentives of mass-tort plaintiff representation. The outcomes of these cases will depend on legal standards, expert witness testimony, and case-specific facts that may or may not track the underlying epidemiology.

Patients should not infer that the existence of lawsuits proves the medication causes harm. Patients should also not dismiss the underlying clinical questions as illegitimate because lawsuits exist. The honest reading is that there is real uncertainty being adjudicated in multiple venues, scientific and legal, and the conclusions may not all align.

What clinical societies recommend for surveillance

The American Diabetes Association, the Endocrine Society, and the American Association of Clinical Endocrinology all maintain their recommendations for GLP-1 receptor agonists in eligible patients without contraindications.

Specific surveillance recommendations:

• No routine ultrasound screening for asymptomatic patients on GLP-1 medications
• No routine calcitonin testing for asymptomatic patients
• Symptom-driven evaluation if new neck lumps, hoarseness, or swallowing difficulty develop
• Patients with prior thyroid abnormalities or family history of thyroid cancer warrant individualized plans with endocrinology
• MTC or MEN-2 history is a contraindication; these patients should not be on the medication in the first place

The surveillance posture reflects the epidemiologic evidence: routine screening of low-risk populations finds many small papillary cancers that may not need treatment and exposes patients to unnecessary biopsies. Symptom-driven evaluation is more clinically useful.

Decision framework for patients on Ozempic with thyroid concerns

If you have personal or family history of MTC or MEN-2:

• You should not be on Ozempic; the contraindication is explicit
• If you are on it, discuss discontinuation with your prescriber
• Continue routine MTC surveillance with endocrinology

If you have other thyroid disease history (nodules, hypothyroidism, papillary cancer):

• Tell your prescriber and endocrinologist before continuing or starting
• Individualized monitoring may be appropriate
• The relative contraindication is weaker than for MTC/MEN-2 but warrants discussion

If you have no thyroid history but are anxious:

• Review the actual evidence base (this article and its sources) with your prescriber
• Recognize the difference between rodent findings and human evidence
• Routine screening is not the answer; symptom awareness is

If you develop concerning thyroid symptoms:

• Report to your clinician within days
• Expect evaluation: physical exam, possibly thyroid ultrasound, possibly fine-needle aspiration
• Continued therapy decisions depend on the findings

The contrary view: when individual reports outweigh population data

The strongest argument for taking case reports more seriously than population data:

Rare events often do not show up cleanly in population studies. If a medication causes thyroid cancer in 1 in 10,000 patients above the baseline rate, the absolute increase is small and may be statistically undetectable even in large databases. A handful of clear case reports could be more informative about a real but rare effect than a null finding in a population study that lacks statistical power for that magnitude of effect.

Long-latency effects are not yet visible. Most population studies of GLP-1 medications have follow-up of 3-5 years. Thyroid cancers can develop over decades. Reassuring data at year 5 does not exclude findings at year 20.

Subgroups may be at differential risk. Population-average data can hide heterogeneity. Patients with specific genetic backgrounds, family history, or other risk factors might experience effects that average data dilute.

Reporting bias cuts both ways. Underreporting of cancer events in GLP-1 patients could mask a real signal. Overreporting due to public awareness could exaggerate one. Without knowing the direction, the population data may be biased in unknown ways.

These arguments justify continued surveillance and ongoing research. They do not, on current evidence, justify avoiding the medication for patients who meet indications and have no contraindications. The reasonable position is to take case reports seriously without treating them as definitive, and to maintain the contraindications strictly.

FAQ

Has anyone gotten thyroid cancer from Ozempic? Cases have been reported in FAERS and in case series. Whether the medication caused these cancers is a separate question; large population studies have not confirmed a measurable increase.

What is FAERS and what do its Ozempic reports show? FAERS is the FDA Adverse Event Reporting System. It is a hypothesis-generating tool subject to selection bias, not a measurement of incidence.

What did the 2024 Wang JAMA study find? The analysis did not find a statistically significant overall increase in thyroid cancer associated with GLP-1 use.

What is the difference between medullary thyroid carcinoma and other thyroid cancers? MTC arises from C-cells and is the cancer type observed in rodent studies. Papillary and follicular cancers arise from different cells and have not shown a clear GLP-1 association.

Are there published case reports of MTC in Ozempic users? Yes. Case reports do not prove causation; they describe associations.

Should I get a thyroid ultrasound while on Ozempic? Routine ultrasound screening of asymptomatic patients is not recommended.

What thyroid symptoms should I report while taking Ozempic? A new lump in the neck, swelling of the thyroid area, persistent hoarseness, trouble swallowing, voice changes, or persistent neck pain.

Are there lawsuits about thyroid cancer and Ozempic? Yes, as of 2026 there is active litigation. Lawsuits are not the same as scientific evidence.

How worried should I be if I am on Ozempic now? For most patients, the available human evidence does not justify high concern, assuming you have no contraindications.

Does the same risk apply to Wegovy? Wegovy is semaglutide at a higher dose. The boxed warning and contraindications are identical.

What if my family history includes thyroid cancer but not MTC? Most family thyroid cancer is papillary, not MTC. The boxed warning specifically addresses MTC; papillary family history is a discussion point but not an absolute contraindication.

Related guides

• Has Anyone Gotten Thyroid Cancer From Mounjaro? Honest Numbers, Honest Limits
• The Ozempic NAION Lawsuit: What the Vision-Loss Cases Actually Allege
• Does Ozempic Show Up on a Drug Test? What Panels Actually Detect
• Thyroid Medication and Ozempic: How Delayed Gastric Emptying Changes Levothyroxine, and What to Do About It
• Does Ozempic Cause Cancer? Separating the Boxed Warning, the Rodent Data, and the Human Evidence
• Counting Clicks in the Ozempic 2 mg Pen: The Dose-Math Patients Actually Want

Sources

1. Wang Y et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Thyroid Cancer. JAMA. 2024.
2. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Semaglutide Reports. Accessed 2026.
3. FDA. Ozempic Prescribing Information (Boxed Warning). 2024 update.
4. Bezin J et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023.
5. Bjerre Knudsen L et al. Glucagon-like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-cells. Endocrinology. 2010.
6. American Diabetes Association. Standards of Care in Diabetes 2025.
7. Endocrine Society. Guidelines on Pharmacotherapy for Obesity. 2024.
8. American Thyroid Association Guidelines for Medullary Thyroid Carcinoma. 2015.
9. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
10. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023.
11. National Cancer Institute SEER Program. Thyroid Cancer Incidence and Survival Statistics. Updated 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed clinicians and U.S. pharmacies. We do not provide direct oncology or endocrinology care. Discussion of pharmacovigilance data here is general and not a substitute for individualized evaluation.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by state-licensed 503A pharmacies and carries the same boxed warning and contraindications as branded Ozempic because the active molecule is the same.

Results Disclaimer. Case reports describe individual patient experiences that may or may not generalize. Population studies describe averages that may miss subgroup or long-latency effects. Both forms of evidence have value and limits.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with Novo Nordisk, Eli Lilly, the FDA, JAMA, or any party involved in current GLP-1 litigation.